261 medicines cannot be sold in a batch of hospitals (with list)

According to the Notice, a total of 103 pharmaceutical enterprises have submitted applications for the scrapping (revocation) of the relevant drug labels, and the winning bid for the above-listed drugs has been disqualified.
according to Seber blue combing, the total number of drugs removed from the net 261, involving ibuprofen dispersion tablets, hot inflammatory particles, blood plug-in tablets, compound three or seven blood tablets, six-flavored yellow pills, Grezier tablets, chlorate tablets, rice Satan tablets, cephalosporadine capsules, hydrochloric acid ooxyfluorosine tablets, rhododendron capsules, azithromycin particles, ribavirin particles, nimodiflat tablets, methazole tablets, hydroxide metformin tablets and other commonly used chemical and traditional Chinese medicine.
Liaoxi Guo pharmaceutical chain Co. , Ltd. practicing pharmacist Li Sibo from a professional point of view to The seiber blue analysis pointed out that from the table of varieties, most of them are basic drugs and low-cost drugs, some are also drugstores often sold varieties, are often purchased by customers.
some of these traditional Chinese medicines are also popular varieties that the public often need to buy.
indeed, after the statistics of Cypress Blue also found that 261 drugs applied for withdrawal mainly from the low-cost drug catalog, obstetrics and gynecology non-patent drug catalog, temporarily not tender editing drug catalog, pediatric non-patented drug catalog, emergency (snatching) drug catalog and so on.
in general, the price of these drugs is not high, basically from a few hairs to a few tens of yuan - such as potassium chloride injection (1g) of the hanging net price of 0.22 yuan, desemipine sodium phosphate injection (2mg) hanging net price of 0.55 yuan, vitamin B6 injection (0.1g) of the net price of 0.63 yuan, vitamin B12 injection (0.5mg) Injection use of moteddine (20mg) hanging net price of 1.9 yuan, Libavirin injection (0.1g) hanging net price of 0.55 yuan, sulphate qing largemycin injection (80mg) hanging net price of 0.78 yuan, Danxiang coronary heart injection (2 ml) of the hanging net price of 0.23 yuan, sodium lactate (500 ml bottle/ 7) hanging price of 8.71yuan.
enterprises to apply for the withdrawal of the network, cut off the supply, sometimes occur in recent times, pharmaceutical companies take the initiative to apply for product saucy to remove the phenomenon of the network can be said to occur frequently.
according to incomplete statistics, as of May this year, drug companies alone actively applied for the withdrawal of more than a thousand drugs.
according to Seipha blue combing, common applications for withdrawal of the network of drugs have heparin sodium injection, hydrochloric acid bubbika because of injection, double yellow granules, Qingkailing injection, hydrochloric acid Benapri tablets, kramycin capsules, compound katoply tablets and other pharmaceutical companies apply for product withdrawal on the general grounds of raw materials rise, production line transformation, pharmaceutical approval was withdrawn and other reasons.
for example, on July 2, the Inner Mongolia Health Insurance Bureau issued a relevant notice shows that, because of the above reasons, Texas German Pharmaceuticals, Shanghai Hyundai Pharmaceuticals and other 20 pharmaceutical companies applied to cancel the registration of 40 drugs, and submitted a national unified non-supply commitment letter.
on the pharmaceutical companies to actively apply for the phenomenon of product withdrawal, Yanjiang Pharmaceutical Marketing Director Huang Yong on the Cypress Blue analysis pointed out that drugs due to production line transformation, raw materials package costs rise, environmental pollution and other reasons caused by the inability to ensure the normal supply of medical institutions, may apply for suspension or revocation of the winning bid network.
, The founder of Beijing Dingchen Pharmaceutical Management Consulting Center Shi Lichen further told Seibrand that it is true that the current situation of drug companies in the provinces frequently withdraw the network is relatively common.
Shi Lichen analysis pointed out that the reason why pharmaceutical companies withdraw the network is mainly because of the previous tender hanging network price is low, and has not been adjusted, with the increase of costs, pharmaceutical companies continue to sell products may face loss of interests, naturally had to make a move to withdraw from the network.
the cost of rising, low-cost drugs can not be low price shried said that in previous years, the price of drug tenders in the country is not linked, different provinces of the network prices are not the same, with the drug tender procurement work between departments, the trend of national linkage of drug prices has been evident, which also makes the withdrawal of enterprises is no longer a single province of the problem. huang Yong,
, further said that based on the overall strategic planning of pharmaceutical companies, product applications to suspend or withdraw the winning bid, is actually a comb inglis of their own products, or even selection - in the current situation of competition in the pharmaceutical industry, there will be more enterprises to self-plan, which as a fist product push, which products temporarily abandoned.
can be said, compared with previous years, the product through marketing, can be based in the market "boom", is the yellow flower of tomorrow.
since then, through the guidance of policies, the response of enterprises, the concentration of the drug market gradually strengthened, the head effect will be more obvious.
for pharmaceutical companies that choose to withdraw from the internet, Shi Lisson suggested that since the policy of public hospitals, primary medical institutions market, or to expand retail terminals, choose to self-pricing retail terminals for sales;
he also said that the current low price is to take, resulting in the continued emergence of enterprise withdrawal, non-supply, and may even affect the normal access to and use of patients drugs;
Shi Lichen suggested that enterprises are for-profit institutions, or need to respect the profitability of pharmaceutical companies, according to the cost of enterprises, the scale of adjustment of drug prices, after all, even without regard to human, hydropower and other costs, the continued rise in the price of raw materials is obvious to all.
the relevant departments have been advocating for drug price monitoring and cost investigation, some industry insiders suggest that price monitoring should not only monitor high-priced, price-rising drugs, but also need to pay attention to low-cost drugs, is about to withdraw from the market.
attached: List of medicines applying for removal from the Internet.